Ftse Mib
36.591,00
0,44%
DAX
21.734,62
0,02%
S&P 500
6.071,17
0,53%
NASDAQ
19.681,75
0,25%
Bitcoin
104.033,40
-0,67%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Biodexa Pharmaceuticals PLC (BDRX) Biodexa Pharmaceuticals PLC (BDRX) Notizie

Biodexa Pharmaceuticals PLC

BDRX
4,24
0,00 (0,00%)
31 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
28/1/202512:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
28/1/202506:15EDGAR2Form EFFECT - Notice of Effectiveness
22/1/202514:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/1/202514:30GLOBEBiodexa Strengthens Management Team - Appointment of Dr Gary..
21/1/202512:30EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
21/1/202512:27EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
21/1/202512:24EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
21/1/202512:21EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
21/1/202512:18EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
21/1/202512:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
21/1/202512:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
17/1/202522:49EDGAR2Form F-1 - Registration statement for certain foreign..
17/1/202522:21EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202512:18EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/1/202512:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/1/202512:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/1/202512:09EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/1/202512:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/1/202512:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/1/202512:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
27/12/202423:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/11/202414:30GLOBEResult of General Meeting
12/11/202422:30EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
12/11/202422:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
12/11/202422:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
12/11/202422:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
12/11/202414:48GLOBEBiodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ..
07/11/202422:51EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
07/11/202422:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/11/202422:30GLOBENotice of General Meeting
05/11/202412:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/11/202412:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/11/202412:09EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/11/202412:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/11/202412:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/11/202412:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
01/11/202422:18EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/10/202415:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
16/10/202415:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
16/10/202415:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
16/10/202415:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/10/202423:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/10/202422:15GLOBEBiodexa Announces Successful Appeal of Nasdaq Delisting
04/10/202414:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202414:30GLOBEBiodexa Provides Update on Progression Free and Overall..
27/9/202422:41EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
27/9/202422:41EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
27/9/202422:41EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
27/9/202422:41EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
Apertura: Min: Max:
Chiusura: 4,24

La tua Cronologia

NASDAQ
BDRX
Biodexa Pharmaceuticals
USOTC
NGHLF
Nightingale Health Oyj (GM)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci